

BURCON NUTRASCIENCE CORPORATION

Price (July 28, 2010)	\$7.00
52-Week Range	\$10.50-\$6.06
Shares O/S	29.1 million
Market Cap	\$203.7 million
50-day Average Volume	14,978
200-day Average Volume	26,069
Fiscal Year-End	March 31
Symbol	TSX-BU
Website	www.burcon.ca

Financial Data

Selected Income/Cash Flow

(C\$ 000; 12 months ended)	Mar-09	Mar-10
Revenues	\$0	\$0
EBITDA	(\$4,887)	(\$6,744)
Net Income	(\$4,811)	(\$6,660)
Cash Flow (CF) From Ops	(\$3,097)	(\$3,846)

Selected Balance Sheet

	At Mar-09	At Mar-10
Cash (& Equivalents)	\$2,242	\$11,662
Shareholders' Equity	\$3,951	\$15,720
Total Assets	\$4,297	\$16,121
Working Capital	\$2,069	\$13,716
Working Capital Ratio	6.96x	35.20x

Per Share Statistics

	At Mar-09	At Mar-10
Earnings Per Share	(\$0.19)	(\$0.23)
Cash Flow Per Share	(\$0.12)	(\$0.13)
Cash Per Share	\$0.09	\$0.40
Equity Per Share	\$0.15	\$0.54

eResearch Analysts:

Bill Campbell, B.Comm
 Bob Weir, B.Sc., B.Comm., CFA

Note: Report prepared with public information only.

eResearch Corporation
 56 Temperance Street, Suite 501
 Toronto, ON M5H 3V5
 Telephone: 416-643-7650
 Toll Free: 877-856-0765



Source: www.bigcharts.com

PROFILE

Burcon NutraScience Corporation (“Burcon” or the “Company”) has built a significant patent portfolio related to its plant protein extraction and purification technologies. The Company currently has 127 issued patents in various countries and over 200 additional patent pending applications, 65 of which are U.S. patent applications.

Burcon’s research is focused on the world’s first commercial canola proteins, Puratein and Supertein, which have important functional and nutritional attributes, and CLARISOY, a soy protein isolate which is 100% soluble and transparent in acidic solutions.

INVESTMENT CONSIDERATIONS

Strengths

- Strong patent portfolio related to its protein extraction and purification technology, with additional patents pending.
- Strong financial position, with no debt and cash of approximately \$14 million (\$0.44 per share), sufficient to fund operations until at least March 2014.
- Major licence and development partner (Archer Daniels Midland Company) to aid in the development, production, and marketing of the canola protein isolates.
- Strong management team, many of whom have been with the Company since its founding in 1999.

INVESTMENT CONSIDERATIONS *(Continued)*

Challenges

- Not yet in commercial production.
- Depending on the nature of the strategic alliance the Company forms for the development of CLARISOY, it may need to raise additional funding to build a production facility for this product.
- Uncertainty in timing of regulatory approvals in the United States, Canada, and Europe.

THE COMPANY

Burcon's head office is in Vancouver, British Columbia, and its laboratory and development facility is in Winnipeg, Manitoba. The Company has developed three main plant-protein isolates. Puratein and Supertein are canola-based, and CLARISOY is a soy-protein isolate.

In September 2003, the Company signed a licence and development agreement with Archer Daniels Midland, to aid in the development, production and marketing of the canola-based isolates on a worldwide basis. By October 2008, the Company had achieved self-affirmed "GRAS" (Generally Regarded as Safe) status for its canola-based isolates for food and beverage applications in the U.S.

The Company was advised in April 2010 by the U.S. Food and Drug Administration (FDA) that its application had been received. Burcon is currently awaiting FDA approval, which may take up to 180 days.

Burcon is also pursuing approval of Puratein and Supertein as "novel foods" from the Food Directorate, Health Products and Food Branch of Health Canada, and in Europe. Approval in Canada and Europe could take between a year and a half and two and a half years.

The Company expects that it will form an alliance with one or more companies to commercialize its CLARISOY soy protein isolate. Burcon is currently exploring strategic alliance opportunities with potential partners. In the second quarter of fiscal 2010, the Company completed a pre-feasibility study with AECOM, a global engineering firm, for the construction and commissioning of an initial CLARISOY production facility. Soy protein health benefits have been recognized by the FDA which, in late 1999, approved the labelling of food products with the following claim: "Diets low in saturated fat and cholesterol that include 25 grams of soy protein daily may reduce the risk of heart disease".

INDUSTRY

The U.S. protein-ingredients market was forecast to generate approximately US\$4.5 billion in revenues in 2008 and to grow at a compound annual rate of 4.5% to 2014. Plant-protein ingredients comprised about 43% of the market, and animal protein 57%. The plant-protein market was expected to grow at a faster rate, as consumers become increasingly aware of plant-protein safety and cost benefits compare with animal protein products. The latter have been adversely impacted by consumer concerns over the effects of animal disease on these products.

Burcon's canola-based products are aimed at two main markets. Puratein is primarily suited for emulsifying, thickening, gelling, binding, aeration, and nutrition. Markets for this product include dressings and sauces, meat substitutes, and baked goods such as protein bars. Supertein is a highly soluble product which is attractive for transparency and foaming. It can be used for beverages, confectionery and aerated desserts.

The Company's soy-based isolate, CLARISOY, is initially targeted at the food and beverage industry, where its advantages over other soy products are its good flavour characteristics as well as 100% solubility and transparency. CLARISOY is particularly attractive in acidic products such as soft drinks, transparent fruit beverages, and sports drinks.

FINANCIALS**(1) Q4/F2010 versus Q4/F2009**

In the fourth quarter of fiscal 2010, Burcon incurred a loss of approximately \$2.0 million (\$0.07 per share) compared with a loss of \$1.8 million (\$0.07 per share) for the corresponding period in fiscal 2009. The latest results included \$908,145 of stock-based compensation costs, compared with \$769,998 in the fourth quarter of fiscal 2009. General and administrative expenses rose 39% in the latest quarter, partly as a result of staff additions.

(\$000s)	<u>Q4/F2010</u>	<u>Q4/F2009</u>
Revenue	0	0
Expenses		
R&D	(740)	(712)
Gen. & Admin.	(855)	(614)
Prof. & Mgm't Fees	(387)	(451)
Amortization	<u>(2)</u>	<u>0</u>
Operating Loss	(1,984)	(1,777)
Interest Income	<u>32</u>	<u>6</u>
Net Loss	(1,952)	(1,771)
EPS	(\$0.07)	(\$0.07)
Shares O/S(million)	28.9	25.4

(2) Full-Year F2010 versus Full-Year F2009

For the full fiscal year 2010, Burcon reported a loss of \$6.7 million (\$0.24 per share) compared with a loss of \$4.8 million (\$0.19 per share) for fiscal 2009. The fiscal 2010 results included stock-based compensation expense of \$2.6 million compared with \$1.5 million in fiscal 2009. All expense categories increased as a result of increased staffing, higher travel and promotional expense related to the development of CLARISOY, increased directors' fees, and costs associated with the Company's TSX listing.

(\$000s)	<u>F2010</u>	<u>F2009</u>
Revenue	0	0
Expenses		
R&D	(2,101)	(2,091)
Gen. & Admin.	(3,177)	(1,554)
Prof. & Mgm't Fees	(1,466)	(1,242)
Amortization	(3)	(2)
Operating Loss	(6,748)	(4,889)
Interest Income	<u>88</u>	<u>78</u>
Net Loss	(6,660)	(4,811)
EPS	(\$0.24)	(\$0.19)
Shares O/S(million)	28.0	25.4

MANAGEMENT & DIRECTORS

Management

Allan Yap:	Chairman & CEO since Nov. 1998. President of Burcon Group Limited (a private real estate and investment company) until July 2007.
Johann F. Tergesen:	President & COO since November 1998.
Jade Cheng:	CFO. President Burcon Group Limited since July 2007.
Dorothy Low:	Senior VP Legal and Corporate Secretary since September 2009. VP Legal from September 2000 to September 2009.
Randy Willardsen:	Senior VP Process of Burcon, and President Willardsen Consulting & Engineering Inc.
Martin Schweiger:	VP Technical Development since September 2009. Manager Technical Development Burcon NutraScience (MB) January 2003 to September 2009.

Directors

Allan Yap	Johann F. Tergesen	Rosanna Chou	Paul Westdal
Stuart MacGregor	Richard O’C Whittall	Lawrence Wang	David Lorne
John Tyrell	Alan Chou		

CORPORATE INFORMATION

Burcon NutraScience Corporation,
1946 West Broadway,
Vancouver, BC, V6J 1Z2
Telephone: 604-733-0896
Website: www.burcon.ca



StockPotentials Reports

The eResearch *StockPotentials* reports are written on companies that eResearch believes have interesting prospects, are smaller in size and, therefore, have little or no following on the Street, and which would benefit from the exposure that eResearch can provide through the dissemination of the reports via our extensive electronic distribution network.

eResearch wrote this report from publicly-available information. Neither a Target Price nor a Recommendation concerning the shares of the Company is provided.

eResearch does not receive a fee for the preparation and publication of *StockPotentials* reports, and Burcon NutraScience Corporation did not pay eResearch a fee for the preparation and publication of this report.

eResearch Corporation

eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential to reach millions of global investors through our extensive electronic distribution network.